Pfizer witnessed a rise in share price on Thursday after the company has entered into an acquisition agreement with AstraZeneca AB, Sweden (AstraZeneca), pursuant to which the brand 'Neksium' is being acquired by the company in India for a consideration of Rs 75 crore, subject to completion of necessary conditions precedent.
Neksium (esomeprazole) complements the company’s existing product portfolio in the gastrointestinal (GI) therapeutic area.
Shares of Pfizer are trading at Rs 1,747.95, up Rs 81.4, or 4.88% at the Bombay Stock Exchange (BSE) on Thursday at 10:13 a.m.
The scrip has touched an intra-day high of Rs 1,785.80 and low of Rs 1,697.00. The total volume of shares traded at the BSE is 6,763.
Total volume of shares traded on the bourses today was higher by 129.32% to 52,259 compared with 22-day average volume of 22,788.